Johnson & Johnson Reports Positive Results for New Crohn’s Disease Treatment
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) revealed encouraging topline results from its Phase 3 GRAVITI study on TREMFYA® (guselkumab) subcutaneous (SC) induction therapy for adults with moderate …
Johnson & Johnson Reports Positive Results for New Crohn’s Disease Treatment Read More